Abstract:e21154 Background: EGFR is expressed extensively on epithelial cells, some of stromal cells and even immune cells. However, little is known about systemic impact of EGFR-TKIs on patients with NSCLC and received TKIs treatment. Here we investigated immunological changes and effects on occurred in patients and mice models exposed in EGFR-TKIs. Methods: In order to identify serum biomarkers associated with EGFR-TKIs treatment, we examined 22 samples of NSCLC patients’ serum cytokines at the time of baseline and progressive disease (PD) by cytokine antibody array. C57BL/6 mice (n = 6/group, repeated 3 times) were randomized to Control, Erlotinib (50 mg/kg qd, i.g, 8 weeks), Osimertinib (5 mg/kg qd i.g, 8 weeks), and Afatinib (15 mg/kg qd i.g, 8 weeks). Using flow cytometry, we examined changes of immune cell subsets. Myeloid-derived suppressor cells were analyzed dynamically. Gene expression profile of MDSC and lung tissue were analyzed using RNA Sequencing. Results: Compare to baseline, five cytokines CCL11, CCL15, CXCL7, HGF, GM-CSF were significantly increased in serum of patients achieved PD which associated with MDSC recruitment and expansion. PMN-MDSC accumulation was found in mice bone marrow and spleen in EGFR-TKIs treatment group. Twenty-five immune-related genes expression were significantly increased in EGFR-TKI group (FDR adjusted p < 0.05), such as S100A8 and S100A9 which associated with poor survival in lung adenocarcinoma. In lung tissue from EGFR-TKI-treated mice ,31 immune-related genes differentially expressed. IHC assay manifested the prevalence of PD-L1 expression on alveolar epithelial cells and vascular endothelium was 11% for Control, 72% for Erlotinib, 83% for Afatinib, 44% for Osimertinib. Conclusions: The immune cells and immune microenvironment were changed following EGFR-TKIs treatment. Our study may provide another explanation for poor response to anti-PD-1 or PD-L1 therapy in NSCLC patients with disease progression following EGFR-TKI therapy. Further studies are currently ongoing for testing the elimination of MDSC combining with anti-PD-1 therapy following EGFR-TKI treatment.

Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.

Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer

P3-015: Clinicopathologic Features and Epidermal Growth Factor Receptor Mutations Associated with Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

Association of Epithelial to Mesenchymal Transition with Efficacy of Egfr-Tkis in Non-Small Cell Lung Cancer Patients with Egfr Wild Type

Role of Epiregulin in Lung Tumorigenesis and Therapeutic Resistance

Epithelial Phenotype As a Predictive Marker for Response to EGFR-TKIs in Non-Small Cell Lung Cancer Patients with Wild-Type EGFR.

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Epiregulin expression and secretion is increased in castration-resistant prostate cancer

EREG is a Risk Factor for the Prognosis of Patients with Cervical Cancer

The Role of EREG/EGFR Pathway in Tumor Progression

Aberrant Epidermal Growth Factor Receptor Signaling And Enhanced Sensitivity To Egfr Inhibitors In Lung Cancer

Cytoplasmic ERß Expression to Predict Efficacy and Survival of EGFR-TKI in EGFR-mutant NSCLC.

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance

Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.

Elevated Epiregulin Expression Predicts Poor Prognosis in Gastric Cancer.

Epiregulin Promotes Migration and Invasion of Salivary Adenoid Cystic Carcinoma Cell Line SACC-83 Through Activation of ERK and Akt

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (Egfr-Tkis) Impact on Immune Microenvironment in Non-Small Cell Lung Cancer (NSCLC).

The EGFR Pathway is Involved in the Regulation of PD-L1 Expression Via the IL-6/JAK/STAT3 Signaling Pathway in EGFR-mutated Non-Small Cell Lung Cancer.

Epiregulin Promotes Lung Metastasis of Salivary Adenoid Cystic Carcinoma.